The civic record
Read. Follow. Verify.Connecticut establishes 28-member advisory council on CAR T-cell and gene therapies for cancer
Last action · April 9, 2026: File Number 566Sponsor: Martha Marx
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Connecticut establishes a 28-member advisory council within the Department of Public Health by July 1, 2026, to advise state agencies on the delivery, safety, and insurance coverage of and other gene therapies.
Establishes a formal state body tasked with evaluating cancer treatment availability, creating centers of excellence, and issuing annual legislative recommendations beginning within one year of its first meeting.
- Chimeric antigen receptor T-cell (CAR T-cell) therapy is a specialized form of immunotherapy that genetically modifies a patient's T-cells to target cancer cells, primarily used for blood cancers. context
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
cancer patients
Patients receiving CAR T-cell therapy and other gene therapies are impacted by newly developed referral networks, safety protocols, psychosocial support methods, and outcome tracking.
clinical providers
Clinicians and providers delivering gene therapies are subject to new advanced training, management protocols, and educational initiatives.
Department of Public Health
The department houses the advisory council for administrative purposes and receives its policy recommendations and annual reports.
Key Facts
- Establishes a 28-member advisory council on chimeric antigen receptor T-cell therapy and other gene therapies within the Department of Public Health for administrative purposes only, effective July 1, 2026.
- Requires initial appointments to the council to be made no later than October 31, 2026, with members serving three-year terms except for state agency representatives.
- Mandates that the first council meeting be scheduled and convened by the acting chairperson no later than November 30, 2026, and that the council meet at least quarterly thereafter.
- Directs the council to advise state agencies on therapy availability, safe and financially sustainable delivery, advanced clinical training, long-term follow-up, and vector safety.
Show all 7 facts
- Authorizes the council to develop centers of excellence, a statewide referral network, safety protocols, psychosocial support methods, and equity-focused patient outcome tracking.
- Empowers the council to apply for and accept grants, gifts, bequests, sponsorships, and in-kind donations, and to enter into necessary contracts or agreements.
- Requires the council to report annually, starting no later than one year after its first meeting, to the joint standing committees of the General Assembly having cognizance of matters relating to public health and insurance.
Frequently Asked Questions
What is the primary role of the newly established advisory council?
Who serves on the advisory council?
How is the council funded?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · on the Senate floor.
Procedural history
9 actions- Apr 9, 2026Connecticut General AssemblyFile Number 566
- Apr 9, 2026SenateSenate Calendar Number 332
- Apr 9, 2026SenateFavorable Report, Tabled for the Calendar, Senate
- Apr 9, 2026Connecticut General AssemblyReported Out of Legislative Commissioners' Office
- Apr 2, 2026Connecticut General AssemblyReferred to Office of Legislative Research and Office of Fiscal Analysis 04/08/26 5:00 PM
- Mar 24, 2026Connecticut General AssemblyFiled with Legislative Commissioners' Office
Show 3 earlier actions
- Mar 23, 2026Connecticut General AssemblyJoint Favorable
- Mar 9, 2026Connecticut General AssemblyPublic Hearing 03/13
- Mar 5, 2026Connecticut General AssemblyCommitteeReferred to Joint Committee on Public Health
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Establishment of Specialized Gene Therapy Oversight
The state is creating a dedicated multi-stakeholder body specifically to manage the clinical delivery, accreditation, and equity tracking of advanced cellular and gene therapies for cancer.
Connected Entities
Sources
cga.ct.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 65)
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools